Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
Covalon Technologies Ltd. announced its participation in the Infusion Nurses Society (INS) 2026 Annual Meeting in Louisville, Kentucky, from April 11‑14. The company will showcase its VALGuard Vascular Access Line Guard and CovaClear IV Cover dressings, emphasizing solutions that protect IV connections from gross contamination. A featured podium presentation by Dr. Nancy Moureau will address the overlooked risk of catheter‑associated bloodstream infections (CABSIs) and propose evidence‑based protection strategies. Covalon aims to demonstrate how its products can lower infection rates and improve patient safety in hospitals and other care settings.
ISG to Study Medical Device Digital Service Providers
Information Services Group (ISG) announced a new Provider Lens® research series called Medical Device Digital Services, scheduled for release in October 2026. The study surveyed over 100 service providers that help medical‑device manufacturers embed AI, cloud, and IoT capabilities into their...
MediStreams Achieves Clean SOC 2 Type II Certification, Strengthening Security in Healthcare Revenue Cycle Management and Payment Automation
MediStreams announced it has received a clean SOC 2 Type II audit for the full 2025 calendar year, covering Security, Availability, and Processing Integrity. The unqualified opinion was issued by independent CPA firm Aprio LLP after a year‑long assessment of its payment‑posting...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous...
Verastem Oncology presented two‑year median follow‑up data from its Phase 2 RAMP 201 trial of the AVMAPKI® FAKZYNJA® combination (avutometinib + defactinib) in recurrent low‑grade serous ovarian cancer (LGSOC). The updated analysis confirmed a median duration of response of 31.1 months and a median progression‑free survival...
Bial Launches Education and Awareness Campaign for World Parkinson’s Day
Bial, the Portuguese biopharma focused on neuroscience, has launched “Dialogues with Parkinson’s,” a year‑long education campaign in partnership with Parkinson’s Europe. The initiative aims to improve communication among patients, caregivers and clinicians to promote earlier diagnosis, especially for the 10‑20%...
Ossium Health Hosts Facility Tour and Reception for Indiana Governor Mike Braun and Healthcare Leaders
Ossium Health hosted a facility tour and reception with Indiana Governor Mike Braun, showcasing its 34,000‑square‑foot Indianapolis plant that houses five ISO 7 cleanrooms and a bone‑marrow banking platform. The company has treated 23 patients using organ donor‑derived bone marrow, underscoring...
New Billboards Tout AHF as Top HIV Provider, Promote STD Testing
AIDS Healthcare Foundation (AHF) launched two national outdoor campaigns, branding itself as “America’s #1 HIV Provider” and promoting free STD testing through the “Peace of Mind” theme. The first campaign highlights AHF’s care for over 234,000 patients across 19 states,...
Vedanta Biosciences Showcases Innovative Work on Its Microbiome-Based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)...
Vedanta Biosciences presented a poster on its eight‑strain consortium VE303 and an oral talk on VE707 at the ESCMID 2026 Congress in Munich. VE303 showed more than an 80% reduction in recurrent Clostridioides difficile infection odds in a Phase 2 trial...
Concentra to Announce First Quarter 2026 Results on Thursday, May 7, 2026
Concentra Group Holdings (NYSE: CON) will release its first‑quarter 2026 earnings on May 7, 2026, after market close, followed by a live webcast earnings call on May 8. The company, the nation’s largest occupational health provider, operates 628 health centers, 411 onsite...
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
Charles River Laboratories announced a partnership with the American Heart Association to back its Heart of Boston campaign, targeting cardiovascular disease awareness and prevention. The collaboration aligns with Charles River’s corporate purpose of creating healthier lives and its broader citizenship...
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences will present new pre‑clinical and clinical data on its Pressure Enabled Drug Delivery™ (PEDD) platform at the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto. The company’s posters and sessions will cover hepatic tumor penetration...
MDRXLaw Launches MDRXResolve: A Smart, Efficient Alternative to Litigation for Healthcare Disputes
MDRXLaw introduced MDRXResolve, a mediation platform tailored for healthcare providers, offering a discreet, efficient alternative to litigation. The service addresses partnership, contractual, regulatory, and employee disputes, aiming to cut costs, reduce delays, and protect operational continuity. Leveraging MDRXLaw’s experience, the...
Athenahealth Targets AI-Driven Patient Discovery with New Rater8 Reputation Management Integration
athenahealth has embedded rater8’s AI‑powered reputation management directly into its athenaOne EHR platform, allowing ambulatory practices to capture reviews, monitor sentiment, and manage directory listings without leaving their clinical workflow. The move is part of athenahealth’s new Alliance Partnerships program,...
Agape Care Group Named USA Today’s Top Workplace for 3rd Consecutive Year
Agape Care Group was named a USA TODAY Top Workplace for the third straight year, based on third‑party employee engagement data from Energage. The hospice provider also earned Top Workplace Culture Excellence Awards across categories such as purpose, wellbeing and...
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More...
GoodRx announced a partnership with Eli Lilly to offer the newly FDA‑approved oral GLP‑1 drug Foundayo (orforglipron) at a self‑pay price of $149 per month. The platform is also rolling out self‑pay pricing for Lilly’s injectable Zepbound (tirzepatide) KwikPen at $299...
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics announced it will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The webcast will be streamed live at 12:45 p.m. ET with a 90‑day replay window. Executives will detail the company’s lead PIKTOR program for endometrial...
NEUPATH HEALTH TO PRESENT AT THE 2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
NeuPath Health Inc. announced that CEO Stephen Lemieux will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026. The 30‑minute virtual session, streamed from the Metro Toronto Convention Centre, will include a live Q&A...
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Cartography Biosciences announced that Gilead Sciences exercised its first option to exclusively license a novel oncology target identified through Cartography’s ATLAS and SUMMIT single‑cell platforms. The target is part of a multi‑year collaboration aimed at tumor‑selective antigens in triple‑negative breast...
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical announced a strategic realignment of its Spine leadership, eliminating the President, Global Spine Solutions role and placing senior executives directly under CEO Massimo Calafiore. Shaeffer Bannigan now oversees overall Spine strategy, while Mark Sienkiewicz and John Winge focus...
MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal
MediFind, the data‑driven online provider directory owned by Phreesia, has become the first doctor directory to earn the Digital Medicine Society (DiMe) Seal. The seal recognizes platforms that meet rigorous standards for clinical evidence, privacy, security, and usability. MediFind leverages...
Latigo Biotherapeutics Appoints Sara M. Bonstein to Its Board of Directors and as Audit Committee Chair
Latigo Biotherapeutics announced that Sara M. Bonstein, CFO of Insmed, has been appointed as an independent director and chair of its audit committee. Bonstein brings more than two decades of biotech financial leadership, having raised over $4 billion for life‑science companies....
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences (NASDAQ: DTIL) announced it will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 9:30 am ET. The virtual session will showcase the company’s ARCUS® gene‑editing platform and its in‑vivo therapeutic pipeline, including programs...
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
Bausch + Lomb received FDA 510(k) clearance for its Bi‑Blade™+ dual‑port vitrectomy cutter and the Adaptive Fluidics update on the Stellaris Elite system. The new cutter operates at 25,000 cuts per minute, a 66% speed boost over the prior model, and delivers a...
Americhem Announces Expansion of Global Healthcare Footprint with New China Investment at Chinaplas 2026
Americhem announced a new clean‑compounding facility in Suzhou, China, slated for the second half of 2026. The plant will be built to ISO 13485 and cGMP standards, extending the company’s regulated healthcare polymer network into Asia. At Chinaplas 2026 the firm will...
VION Biosciences Closes Acquisition of CTL, Strengthening Functional Immune Monitoring Capabilities
VION Biosciences announced the closing of its acquisition of Cellular Technology Limited (CTL), adding ELISPOT and FluoroSpot analyzers, software, consumables, and assay services to its portfolio. The deal enhances VION’s ability to provide functional immune‑monitoring solutions across translational and clinical...
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
Hemispherian AS announced the initiation of a first‑in‑human Phase 1/2a trial of GLIX1 in patients with recurrent glioblastoma and other high‑grade gliomas. GLIX1 is an oral, first‑in‑class small‑molecule TET2 activator that induces tumor‑selective DNA damage and has demonstrated potent preclinical efficacy,...
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation will present a slate of scientific abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) meeting in Washington, D.C., and will exhibit at booth #407. The company is also sponsoring an educational symposium on Epioxa™,...
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb announced it will present 45 scientific papers and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., from April 9‑13, 2026. The sessions will feature data on its ELIOS minimally‑invasive...
MedTech Innovator Radar Forum April 7-9 Levels Up MedTech Industry’s Most Rigorous Evaluation Platform and Leading Accelerator Program
MedTech Innovator is debuting the Radar Forum, a single, invite‑only event held April 7‑9, 2026 in Manhattan Beach that replaces its previous multi‑city road‑tour pitches. The three‑day forum will host roughly 500 attendees, including 300 top experts who will evaluate the top...
Spacelabs Healthcare Announces Agreement to Provide Its Rothman Index® to Hospitals and Health Systems Through DEPTH Health
Spacelabs Healthcare has signed an agreement with DEPTH Health to integrate its Rothman Index into DEPTH’s Real‑Time Advisor for Clinical Expert Routing (RACER) platform. The Rothman Index aggregates 26 clinical data points into a 200‑point risk score that updates continuously,...
After an Autism Diagnosis: Expert Guidance From Acorn Health
April marks Autism Acceptance Month, prompting families to confront new autism diagnoses. Acorn Health’s executive vice president Krista Orellana outlines five practical steps for parents, from emotional processing to securing insurance‑covered services. The guidance emphasizes early, evidence‑based ABA therapy as...
Agenus Announces Data From Phase II Study of BOT+BAL in Combination with Agent-797 in PD-1 Refractory Gastroesophageal Cancer to Be...
Agenus announced that data from an investigator‑initiated Phase II trial of its multi‑mechanistic immunotherapy combo—botensilimab (BOT), balstilimab (BAL) and the allogeneic iNKT cell therapy agenT‑797—will be presented at the AACR Annual Meeting in April 2026. The study targets patients with PD‑1‑refractory gastroesophageal...
Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences (Nasdaq: PLSE) will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 9:30 am ET. The company will showcase its proprietary nPulse™ platform, which uses nanosecond pulsed field ablation (nsPFA™) to treat atrial fibrillation and...
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care (Nasdaq: TNDM) will release its first‑quarter 2026 financial results on May 7, 2026, after the market closes. A conference call and live webcast will begin at 4:30 pm Eastern Time, with a 30‑day archived replay on the investor website. The...
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
CONMED Corporation (NYSE: CNMD) announced it will report its first‑quarter 2026 financial results after the market close on Wednesday, April 29, 2026. Management will host a conference call at 4:30 p.m. ET the same day, with a live webcast and a...
SV Health Investors Acquires EpiVax
SV Health Investors (SVHI) announced the acquisition of EpiVax, a Providence‑based bioanalytical CRO that specializes in immunogenicity risk assessments for pharma and biotech firms. The deal adds a proven scientific platform, including the ISPRI predictive software and cell‑based assays, to...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Novocure to Report First Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) announced it will disclose its first‑quarter 2026 financial results on April 30, 2026, before U.S. markets open. Management will host a conference call at 8:00 a.m. EDT, accompanied by a live webcast and slide deck available on the investor‑relations...
Bruker Announces Appointment of Thierry Bernard to Its Board of Directors
Bruker Corporation announced that Thierry L. Bernard has been appointed to its Board of Directors, effective immediately. Bernard, currently chief executive of QIAGEN, will step down after a successor is named. He brings decades of leadership in life‑science tools and diagnostics,...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
CapVest Completes Majority Acquisition of Stada
CapVest Partners LLP has completed the acquisition of a majority stake in Germany’s STADA Arzneimittel AG, a leading consumer‑health, generics and specialty pharma group. The deal follows STADA’s record 2025 performance, with revenue of €4.3 billion (approximately $4.73 billion) and adjusted EBITDA of €961 million...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
AI Med Consult and 4D EMR Announce Strategic Partnership to Advance AI-Driven Patient Engagement and Practice Efficiency
AI Med Consult and 4th Dimension EMR announced a strategic partnership at the AACS Annual Scientific Meeting, integrating AI‑driven patient engagement tools with 4D EMR’s aesthetic‑medicine platform. The combined solution will feed real‑time interaction data into electronic medical records, delivering...
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program...
Bristol Myers Squibb announced the evolution of its Standing in the Gaap program, expanding its reach to address equity gaps in multiple myeloma care. The initiative will launch one of the largest U.S. multiple myeloma surveys, targeting more than 1,000...
